2021 Report on Radiation Toxicity Drugs In Development – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Radiation Toxicity – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline landscape. Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue.

It provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 12, 8, 1, 50, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 6, 1 and 1 molecules, respectively. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).
• The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology)

Companies Mentioned

• 21st Century Therapeutics Inc
• 9 Meters Biopharma Inc
• Advanced Innovative Partners Inc
• Advenchen Laboratories LLC
• Allander Biotechnologies LLC
• Amryt Pharma Plc
• Angion Biomedica Corp
• Aqualung Therapeutics Corp
• Atox Bio Ltd
• BCN Biosciences LLC
• BioCurity Pharmaceuticals Inc
• BioIncept LLC
• Bolder Biotechnology Inc
• Cellphire Inc
• Ceramedix Holding LLC
• Ceramide Therapeutics LLC
• Chrysalis BioTherapeutics Inc
• Cleveland BioLabs Inc
• Clevexel Pharma SA
• Connext Co Ltd
• Consegna Pharma Inc
• Creative Medical Technology Holdings Inc
• Eagle Pharmaceuticals Inc
• Enveric Biosciences Inc
• Enzychem Lifesciences Corp
• EpicentRx Inc
• Exponential Biotherapies Inc
• Extend Biosciences Inc
• Fibroplate Inc
• FirstString Research Inc
• Foresee Pharmaceuticals Co Ltd
• Genexine Inc
• Genome Protection Inc
• GNI Group Ltd
• Humanetics Corp
• Inflammatory Response Research Inc
• iNtRON Biotechnology Inc
• Lutris Pharma
• Luxena Pharmaceuticals Inc
• Matrix Biomed Inc
• Meabco AS
• Medesis Pharma SA
• Neumedicines Inc
• Neuropathix Inc
• New Amsterdam Sciences Inc
• Novartis AG
• Noveome Biotherapeutics Inc
• Onconova Therapeutics Inc
• Original BioMedicals Co Ltd
• Oxacell AG
• P2D Inc
• Perpetuum BV
• PharmaIN Corp
• Phoenicia Biosciences Inc
• Pluristem Therapeutics Inc
• Regeneus Ltd
• RepoCeuticals ApS
• RxBio Inc
• Soligenix Inc
• Sunny Pharmtech Inc
• Synedgen Inc
• TheraSource LLC
• Tonix Pharmaceuticals Holding Corp
• Valenta Pharm
• VasoDynamics Ltd
• Vera Salus Ricerca Srl
• Worphmed Srl

For more information about this report visit https://www.researchandmarkets.com/r/49rxfu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900